Can Doripenem Be Used for Respiratory Infections?
Yes, doripenem can be used for respiratory infections, specifically nosocomial pneumonia including ventilator-associated pneumonia, where it demonstrates comparable efficacy to other carbapenems like meropenem and imipenem. 1
Approved Indications for Respiratory Use
Doripenem is specifically approved for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP) in the Asia-Pacific region and has been studied extensively for these indications. 2
Clinical Efficacy Evidence
Nosocomial Pneumonia Performance
- Doripenem shows similar efficacy to comparator carbapenems (imipenem, meropenem, piperacillin/tazobactam) for nosocomial pneumonia, with comparable clinical cure rates, microbiological cure rates, all-cause mortality, and adverse event profiles. 3
- In a large prospective study of 216 patients across the Asia-Pacific region, doripenem achieved clinical cure rates of 86.7% at end of therapy and 87.1% at test of cure in clinically evaluable patients with NP/VAP. 2
- Direct comparison with meropenem in HAP/VAP patients showed no survival difference in 30-day mortality (log-rank p = 0.113), confirming non-inferiority. 4
Spectrum of Activity
- Doripenem exhibits broad-spectrum activity against common nosocomial respiratory pathogens including extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. 5
- It demonstrates better in vitro activity against P. aeruginosa compared to other anti-pseudomonal carbapenems, combining the Gram-positive activity of imipenem with the Gram-negative spectrum of meropenem. 6
Important Clinical Caveats
Population-Specific Concerns
- Avoid doripenem in patients with hematological malignancies, as poorer outcomes were observed in this subgroup compared to meropenem (log-rank p = 0.012). 4
- Guideline recommendations now favor meropenem as the preferred carbapenem alternative when doripenem is mentioned, likely reflecting its discontinuation status. 1
Dosing and Administration
- Standard dosing is 500 mg intravenously infused over 1 hour or 4 hours every 8 hours for 5-14 days. 2
- For carbapenem-resistant P. aeruginosa with intermediate susceptibility (MIC 4-8 mg/L), high-dose 4-hour infusions combined with fosfomycin produce outcomes comparable to colistin-based regimens. 1
- Dosage adjustment is required for patients with renal impairment. 6
Guideline Context
While doripenem is listed alongside imipenem, meropenem, and piperacillin-tazobactam as appropriate empiric therapy for hospital-acquired infections in critically ill patients 1, it is not mentioned in current community-acquired pneumonia guidelines 7, limiting its use to nosocomial respiratory infections only.
Safety Profile
Common adverse effects include headache, nausea, and diarrhea (1.4% each). 2, 6 The drug is generally well-tolerated with a safety profile similar to other carbapenems. 3